Jefferies Group LLC started coverage on shares of Assembly Biosciences Inc (NASDAQ:ASMB) in a research note issued to investors on Wednesday, November 8th, Marketbeat Ratings reports. The brokerage issued a buy rating and a $50.00 price objective on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Assembly Biosciences’ Q4 2017 earnings at ($0.92) EPS, FY2017 earnings at ($3.49) EPS, FY2018 earnings at ($3.22) EPS, FY2019 earnings at ($3.54) EPS and FY2020 earnings at ($3.31) EPS.
ASMB has been the topic of several other reports. Chardan Capital restated a buy rating on shares of Assembly Biosciences in a research report on Sunday, September 17th. BidaskClub upgraded shares of Assembly Biosciences from a buy rating to a strong-buy rating in a research report on Thursday, August 24th. Finally, Zacks Investment Research upgraded shares of Assembly Biosciences from a sell rating to a hold rating in a research report on Tuesday, October 10th.
Assembly Biosciences (NASDAQ:ASMB) opened at $41.84 on Wednesday. Assembly Biosciences has a 1-year low of $11.07 and a 1-year high of $45.52.
A number of hedge funds and other institutional investors have recently made changes to their positions in ASMB. Vanguard Group Inc. raised its stake in Assembly Biosciences by 21.2% during the second quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock worth $12,615,000 after purchasing an additional 107,065 shares during the period. State Street Corp purchased a new position in Assembly Biosciences during the second quarter worth approximately $4,234,000. Northern Trust Corp raised its stake in Assembly Biosciences by 221.2% during the second quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock worth $4,033,000 after purchasing an additional 134,513 shares during the period. JPMorgan Chase & Co. raised its stake in Assembly Biosciences by 6.9% during the third quarter. JPMorgan Chase & Co. now owns 177,312 shares of the biopharmaceutical company’s stock worth $5,944,000 after purchasing an additional 11,412 shares during the period. Finally, Lyon Street Capital LLC raised its stake in Assembly Biosciences by 9.7% during the third quarter. Lyon Street Capital LLC now owns 149,443 shares of the biopharmaceutical company’s stock worth $5,219,000 after purchasing an additional 13,243 shares during the period. Hedge funds and other institutional investors own 61.88% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Assembly Biosciences Inc (ASMB) Now Covered by Analysts at Jefferies Group LLC” was published by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/jefferies-group-llc-begins-coverage-on-assembly-biosciences-inc-asmb/1768021.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with our FREE daily email newsletter.